The quality of life impact of the COVID-19 pandemic and lockdowns for people living with multiple sclerosis (MS): evidence from the Australian MS Longitudinal Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Netherlands Country of Publication: Netherlands NLM ID: 9210257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2649 (Electronic) Linking ISSN: 09629343 NLM ISO Abbreviation: Qual Life Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : Netherlands : Springer Netherlands
      Original Publication: Oxford, UK : Rapid Communications of Oxford, Ltd, c1992-
    • Subject Terms:
      COVID-19*/psychology ; COVID-19*/epidemiology ; Multiple Sclerosis*/psychology ; Quality of Life* ; SARS-CoV-2*; Humans ; Female ; Male ; Middle Aged ; Longitudinal Studies ; Surveys and Questionnaires ; Aged ; Australia ; Victoria ; Adult ; Pandemics ; Quarantine/psychology
    • Abstract:
      Purpose: People living with multiple sclerosis (PwMS) in metropolitan Victoria, Australia, experienced a 112-day, COVID-19-related lockdown in mid-2020. Contemporaneously, Australian PwMS elsewhere experienced minimal restrictions, resulting in a natural experiment. This study investigated the relationships between lockdowns, COVID-19-related adversity, and health-related quality of life (HRQoL). It also generated health state utilities (HSU) representative of changes in HRQoL.
      Methods: Data were extracted from Australian MS Longitudinal Study surveys, which included the Assessment of Quality of Life-Eight Dimensions (AQoL-8D) instrument and a COVID-19 questionnaire. This COVID-19 questionnaire required participants to rank their COVID-19-related adversity across seven health dimensions. Ordered probits were used to identify variables contributing to adversity. Linear and logit regressions were applied to determine the impact of adversity on HRQoL, defined using AQoL-8D HSUs. Qualitative data were examined thematically.
      Results: N = 1666 PwMS (average age 58.5; 79.8% female; consistent with the clinical presentation of MS) entered the study, with n = 367 (22.0%) exposed to the 112-day lockdown. Lockdown exposure and disability severity were strongly associated with higher adversity rankings (p < 0.01). Higher adversity rankings were associated with lower HSUs. Participants reporting major adversity, across measured health dimensions, had a mean HSU 0.161 (p < 0.01) lower than participants reporting no adversity and were more likely (OR: 2.716, p < 0.01) to report a clinically significant HSU reduction. Themes in qualitative data supported quantitative findings.
      Conclusions: We found that COVID-19-related adversity reduced the HRQoL of PwMS. Our HSU estimates can be used in health economic models to evaluate lockdown cost-effectiveness for people with complex and chronic (mainly neurological) diseases.
      (© 2024. The Author(s).)
    • References:
      Mult Scler. 2020 Sep;26(10):1153-1156. (PMID: 32552382)
      Mult Scler. 2013 Oct;19(12):1627-31. (PMID: 23530001)
      Disabil Rehabil. 2023 Feb;45(4):630-643. (PMID: 35166613)
      PLoS One. 2020 Nov 4;15(11):e0241658. (PMID: 33147259)
      EClinicalMedicine. 2021 Apr;34:100796. (PMID: 33754138)
      Mult Scler Relat Disord. 2021 Aug;53:103042. (PMID: 34091177)
      Neurol Ther. 2021 Jun;10(1):279-291. (PMID: 33855692)
      Qual Life Res. 2016 Dec;25(12):3209-3219. (PMID: 27344318)
      PLoS One. 2022 Apr 7;17(4):e0266650. (PMID: 35390076)
      Med Decis Making. 2015 Apr;35(3):292-304. (PMID: 25623064)
      Lancet Neurol. 2006 Nov;5(11):932-6. (PMID: 17052660)
      Qual Life Res. 2023 Feb;32(2):339-355. (PMID: 35989367)
      Pharmacoecon Open. 2018 Dec;2(4):443-458. (PMID: 29623636)
      BMC Public Health. 2021 May 27;21(1):988. (PMID: 34039306)
      Health Econ. 2022 Feb;31(2):284-296. (PMID: 34773325)
      J Health Serv Res Policy. 2021 Jul;26(3):189-197. (PMID: 33337256)
      Qual Life Res. 2021 May;30(5):1389-1405. (PMID: 33389523)
      Neurology. 2006 Jun 13;66(11):1696-702. (PMID: 16769943)
      Mult Scler Relat Disord. 2021 May;50:102798. (PMID: 33571791)
      PeerJ. 2021 Jul 22;9:e11767. (PMID: 34327055)
      Eur J Neurol. 2021 Oct;28(10):3375-3383. (PMID: 33043560)
      Lancet. 2018 Apr 21;391(10130):1622-1636. (PMID: 29576504)
      Indian J Psychiatry. 2020 Jul-Aug;62(4):354-362. (PMID: 33165368)
      Lancet Neurol. 2018 Feb;17(2):162-173. (PMID: 29275977)
      Br J Pain. 2021 Aug;15(3):357-368. (PMID: 34377461)
      Soc Sci Med. 2005 Feb;60(4):789-97. (PMID: 15571896)
      BMJ. 2016 Feb 10;352:i563. (PMID: 26865572)
      Patient. 2014;7(1):85-96. (PMID: 24271592)
      Mult Scler. 2021 Jul;27(8):1262-1275. (PMID: 32924841)
      Gen Psychiatr. 2020 Mar 6;33(2):e100213. (PMID: 32215365)
      Psychiatry Res. 2020 Jun;288:112954. (PMID: 32325383)
      Mult Scler. 2020 Dec;26(14):1816-1821. (PMID: 33174475)
      Mult Scler. 2013 Oct;19(12):1640-6. (PMID: 23652216)
      JAMA. 2021 Feb 23;325(8):765-779. (PMID: 33620411)
      Monash Bioeth Rev. 2022 Jun;40(1):62-93. (PMID: 35088370)
    • Grant Information:
      19-0702 Multiple Sclerosis Australia
    • Contributed Indexing:
      Keywords: Australia; COVID-19; Health economics; Multiple sclerosis; Quality of life
    • Publication Date:
      Date Created: 20240405 Date Completed: 20240523 Latest Revision: 20240908
    • Publication Date:
      20240909
    • Accession Number:
      PMC11116258
    • Accession Number:
      10.1007/s11136-024-03620-4
    • Accession Number:
      38578380